October 26, 2016 5:47 AM ET


Company Overview of Liventa Bioscience

Company Overview

AFCell Medical, Inc. produces and supplies amniotic membrane-based biomaterial technology solutions. The company offers amnion, as well as other birth tissue products, such as chorion and amniotic fluids. It also provides AmnioClear, a human allograft membrane transplant for surgical use and to be placed over damaged internal membranes. The company was formerly known as PearlDiver Technologies, Inc. and changed its name to AFCell Medical, Inc. in September 2011. AFCell Medical, Inc. was founded in 2006 and is based in Parsippany, New Jersey.

322 Route 46W

Suite 150

Parsippany, NJ 07054

United States

Founded in 2006





Key Executives for Liventa Bioscience

Founder and Chief Executive Officer
Chief Operating Officer
Age: 54
Compensation as of Fiscal Year 2016.

Liventa Bioscience Key Developments

MiMedx Group, Inc. Reaches Settlement with Medline Industries and Liventa Bioscience for Certain Claims

MiMedx Group, Inc. announced that the company has agreed to terms of settlement with each of Medline Industries, Inc. and Liventa Bioscience, Inc. for false advertising claims asserted against each of them by MiMedx. In April 2014, MiMedx filed a lawsuit in the United States District Court for the Northern District of Georgia against Musculoskeletal Transplant Foundation, Inc., Medline, and Liventa for permanent injunctive relief and unspecified damages. In its suit, MiMedx asserted that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients and in some cases, prospective investors. In addition to the allegations of false advertising, the lawsuit also asserted that MTF, Liventa and Medline infringed several MiMedx patents. The various false advertising claims asserted by MiMedx in its lawsuit included false advertising in violation of the Lanham Act; unfair competition in violation of the Lanham Act; false advertising in violation of the Georgia False Advertising Statue; and deceptive trade practices in violation of the Georgia Deceptive Trade Practices Act.

The Musculoskeletal Transplant Foundation Reconfirms Favorable Ruling from the Patent Trial and Appeal Board

The Musculoskeletal Transplant Foundation (MTF) reconfirmed on September 1, 2015 that the Patent Trial and Appeal Board of the United States Patent and Trademark Office has ruled in favor of MTF's inter partes review challenge to the EpiFix patent (U.S. Patent No. 8,372,437) asserted in the related lawsuit brought by MiMedx Group, Inc. against MTF, Liventa Bioscience, Inc., and Medline Industries, Inc. The '437 Patent is the initial patent in a family that includes two other EpiFix patents involved in the MiMedx lawsuit (US Patent Nos. 8,597,687 and 8,709,494).

MiMedx Group, Inc. Receives Favorable Rulings from Patent Trial and Review Board against Lawsuit of Liventa Bioscience, Inc., Medline Industries, Inc., Musculoskeletal Transplant Foundation, Inc., Transplant Technology, Inc. and Texas Human Biologics Ltd

MiMedx Group, Inc. announced the Patent Trial and Appeal Board has ruled in favor of the company's primary EpiFix and AmnioFix patents. In April 2014, MiMedx filed patent infringement lawsuits in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc., Medline Industries, Inc. and Musculoskeletal Transplant Foundation, Inc. for permanent injunctive relief and unspecified damages. In May 2014, the company also filed a separate action against Transplant Technology, Inc. d/b/a Bone Bank Allograft and Texas Human Biologics Ltd. for patent infringement. In both suits, MiMedx asserted that these organizations infringed and continue to infringe at least six MiMedx patents. As part of their defense strategy, two of the four defendants submitted certain of the MiMedx patents to the inter partes review process, which means they are asking the PTAB to review the subject matter covered by the MiMedx patents and decide whether it was proper for the patents to have been granted in the first place. MiMedx received two recent rulings from the PTAB. One PTAB ruling was made in regard the inter partes review request related to the MiMedx primary EpiFix patent and the other recent PTAB decision was for the inter partes review request related to the MiMedx AmnioFix patent. In both rulings, the PTAB found no basis to challenge these patents and fully rejected the request for review on these patents.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Liventa Bioscience, please visit www.afcellmedical.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.